Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Annals of Hematology|October 31, 2009
Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admissionSyed W I Bokhari, Talha Munir, Shabeeha Memon, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 19, 2016
Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral MethotrexateTalha Munir, Mark J Bishton, Ian Carter, et al.
Advances in Therapy|June 11, 2026
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-UpMazyar Shadman, Talha Munir, Sheng Xu, et al.
Future Oncology (London, England)|November 1, 2025
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohortTalha Munir, Danielle Leão, Boo Messahel, et al.
Ejhaem|August 21, 2023
Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuriaAnna Gaya, Talha Munir, Alvaro Urbano-Ispizua, et al.
Trials|September 21, 2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialDena R Howard, Talha Munir, Anna Hockaday, et al.
Trials|July 28, 2017
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trialJamie B Oughton, Laura Collett, Dena R Howard, et al.
Blood Advances|January 26, 2026
An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLLMazyar Shadman, Constantine S Tam, Danielle M Brander, et al.
British Journal of Haematology|August 26, 2022
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trialTalha Munir, Jake Emmerson, Anna Hockaday, et al.
Oncology and Therapy|September 13, 2025
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTalha Munir, Nicolás Martinez-Calle, Sheng Xu, et al.
Pageof 7